Both anti-VEGF and laser therapies have similar efficacy in preventing progression and recurrence, but anti-VEGF treatment may be associated with a lower risk of structural adverse effects and high myopia compared to laser treatment [73,74,75]. This evidence concerns the gene VEGFA and myopia.